Health

Maternal and Child Health

  • Infectious Diseases
    Why Hasn’t the World Eradicated Polio?
    The world is inching closer to eradicating polio, but armed conflicts and opposition to vaccines stand in the way of finally eliminating the disease.
  • Latin America
    What Colombia’s Legalization of Abortion Means for Latin America
    Latin America has historically had some of the world’s most restrictive abortion policies, but Colombia’s easing of rules signals a growing wave of change.
  • Health
    Renewing America Series: Public Health as a Public Good—What's at Stake?
    Play
    The COVID-19 pandemic amplified health disparities and renewed conversations about the limitations of current public health systems after decades of disinvestment. Panelists explore the idea of reframing public health as a public good to drive investment, modernization, and encourage better coordination across health systems. With its Renewing America initiative, CFR is evaluating nine critical domestic issues that shape the ability of the United States to navigate a demanding, competitive, and dangerous world.  
  • Pharmaceuticals and Vaccines
    The COVID-19 Vaccination Challenge: Lessons From History
    Vaccines are a major public health success story, but the COVID-19 pandemic underscores the many challenges involved in getting a vaccine to everyone who needs it.
  • Pharmaceuticals and Vaccines
    Good News Emerges About a Malaria Vaccine
    In Africa and elsewhere, COVID-19 dominates media attention. Yet malaria has probably killed four times as many as COVID-19 over the last year in Africa. The disease is caused by a parasite, plasmodium, not a virus or a bacterium. The disease confers no immunity and an individual can catch it repeatedly; in parts of Africa, individuals catch malaria on an annual basis. Europeans had no immunity to malaria, and the disease killed so many that it, in effect, closed West Africa to them. The good news is that early trials of a new vaccine, R21, show an effectiveness rate of 77 percent. Still to be determined is how long the vaccine will be effective. Work on a vaccine against malaria has been underway for years, with remarkably little success. Part of the difficulty is related to the parasitic nature of the disease—parasites are more complex than viruses or bacterium. Part of the answer has been relatively low investment in the search for a vaccine by pharmaceutical companies; the disease mostly affects the poor in lower-income countries. The new vaccine is a further development of Mosquirix, a vaccine with a 56 percent effectiveness after one year, falling to 36 percent after four years. Mosquirix was developed by GlaxoSmithKline in collaboration with the (U.S.) Walter Reed Army Institute of Research and PATH, a nonprofit health organization. To spread, the disease requires an insect vector—a female Anopheles mosquito—and human blood. In humans, the parasite migrates to the liver and from there to the bloodstream. A mosquito can bite an infected human and then spread the disease by biting another human. In adults, the disease is rarely fatal, except among pregnant women and those with weak or compromised immune systems, and the severity of the symptoms decreases as individuals age. Fatalities are primarily among infants and children, not the elderly. Among adults, the disease resembles influenza, with fever, chills, and fatigue. In terms of loss of human participation in the economy, malaria is a huge burden on Africa. Up to now, malaria prevention has been centered on the mosquito: insecticide-treated bed nets are an effective, low-cost intervention, while various prophylactics can also blunt the disease’s progression following infection.
  • Health
    Let’s Talk About Toilets
    Podcast
    Fifty-five percent of the global population lacks access to safe sanitation, a deadly global health disparity that rarely finds its way into the spotlight. In this episode, we examine the scope of the problem, and the cultural challenges that have made it surprisingly difficult to fix.